Jiangsu Zhonghe Pharmaceutical Technology

Jiangsu Zhonghe Pharmaceutical Technology is a biopharmaceutical research and development company headquartered in Taizhou, China, within the China Medical City (CMC) hub. The company specializes in the development of high-end generic drugs and innovative small molecule therapeutics, with a strong focus on targeted therapies for oncology and autoimmune diseases. Its core competencies include complex chemical synthesis, crystal form optimization, and advanced formulation development. Jiangsu Zhonghe operates a business model centered on technology transfer and collaborative development, providing pharmaceutical manufacturers with ready-to-file dossiers for abbreviated new drug applications (ANDAs). The company's portfolio includes several successfully commercialized kinase inhibitors and other critical treatments for the Chinese market. It is recognized as a High-tech Enterprise and plays a significant role in the regional pharmaceutical innovation ecosystem.